ArticleInternational journal of clinical and experimental pathology2017
Propofol alleviates hepatic ischemia/reperfusion injury via the activation of the Sirt1 pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Trial
- Non-anesthetic Effects of Anesthetics and Organ Protection.Current neuropharmacology · 2026Review
- Sufentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats by regulating ferroptosis through ATF3.BMC anesthesiology · 2025Article
- Propofol reduces lipopolysaccharide‑induced cardiomyocyte injury in sepsis by activating SIRT1‑mediated autophagy.Experimental and therapeutic medicine · 2023Article
- Effects of remifentanil and propofol on distant organ lung injury in an ischemia-reperfusion model.Open medicine (Warsaw, Poland) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPropofol exerts protective effects on multiple organs, including the liver. The aim of the present study was to investigate whether the protective effects of propofol on the liver are related to Sirt1, an NAD
methodsAfter treatment with propofol, hepatic I/R injury was induced in mice. Liver injury, oxidative stress, antioxidant capacity, cytokine production, and apoptotic markers were investigated to assess the effects of propofol pretreatment on hepatic I/R injury. The expression of Sirt1 was assessed by immunohistochemical and western blot analyses, and the expression levels of NF-κB/p65, IκBα, Bcl-2 and Bax were analyzed by western blot.
resultsAfter 70% hepatic I/R injury, the mice that were pretreated with propofol showed considerably less liver injury, enhanced anti-inflammatory and antioxidant capacity, and less apoptosis. Additional studies revealed that propofol pretreatment prior to I/R injury results in reduced NF-κB activation and apoptosis through Sirt1 activation.
conclusionsThe present study is the first to reveal that propofol can significantly reduce hepatic I/R injury by regulating the expression of Sirt1, and these effects may be related to anti-inflammatory and antioxidant effects. Our results suggest that propofol may be an effective therapeutic strategy for the treatment of hepatic I/R injury in hepatobiliary surgery.
Indexed as
Identifiers
31966440PMC6965884W3009925855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.